BioSpace News Archive

Until recently, the occurrence of serious fungal infections had been fairly uncommon. However, with a rapid increase in systemic infections, the global market for fungal infections is slated for tremendous progress over the next few years.

Dr. Lana Gerzenshtein, PharmD, BCPS, CSP, Manager of Network Clinical Programs at Excelera to speak at the virtual summit to share expertise on clinical outcomes initiatives and opportunities within health system-based specialty pharmacies [24-August-2020] MINNEAPOLIS , Aug. 24, 2020 /PRNewswire/ -- Excelera® , the company behind the Excelera Network, announced today

Mallinckrodt Pharmaceuticals, a global biopharmaceutical company, announced that its Specialty Generics business has been recognized as a Manufacturing Leadership Award winner for outstanding achievement by the National Association of Manufacturers.

Quest to dedicate more than $100 million to expand access to testing, partner to help those hit hardest by COVID-19 and fund Foundation initiatives

Considerations and challenges in inhalation toxicology to include small molecules, proteins, peptides and gene therapy aerosol delivery

Protalix BioTherapeutics, Inc., a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, announced completion of the treatment period of its Phase III BRIGHT clinical trial of pegunigalsidase alfa, or PRX–102, for the proposed treatment of Fabry disease.

Orchard Therapeutics, a global gene therapy leader, announced presentations at the upcoming 46th Annual Meeting of the European Society for Blood and Marrow Transplantation, taking place virtually from August 29 - September 1, 2020.

TRV027 is a novel AT1 receptor selective agonist with the potential to treat acute lung damage / abnormal blood clotting associated with COVID-19

Medtronic plc announced that its Board of Directors appointed Kevin Lofton to the Board as an independent director, effective September 15, 2020.

This is the Company’s third FDA-cleared indication for its Deep TMS System, and is the first FDA clearance in the addiction space for any TMS device